Cordance Medical

Cordance Medical is pioneering a non-invasive, focused ultrasound-based platform to transiently and locally open the blood-brain barrier, a major obstacle in treating and diagnosing neurological disorders. The company's NeuroAccess system is designed to enhance drug delivery to the brain and allow for blood-based biomarker sampling ('sonobiopsy'), targeting indications like brain cancer, Alzheimer's, Parkinson's, and epilepsy. With a seasoned leadership team, key FDA regulatory recognition, and a platform approach, Cordance is positioning itself to unlock a significant unmet need in neurotherapeutics and diagnostics.

NeuroAccess system: a non-invasive medical device using low-frequency focused ultrasound and microbubbles to reversibly and locally open the blood-brain barrier for enhanced drug delivery and diagnostic biomarker sampling (sonobiopsy).

Cordance competes in the emerging field of BBB modulation, which includes other focused ultrasound companies (e.g., Insightec), invasive implantable device approaches, and pharmaceutical methods (e.g., receptor-mediated transport). Its focus on a non-invasive, outpatient-friendly platform for both drug delivery and diagnostics is a key differentiator.